Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECHO/ICU: Helium/Oxygen in Severe COPD Exacerbations
NCT01155310Phase 3Terminated
- Sponsor
- Air Liquide
- Start
- May 2010
- Primary completion
- Oct 2013
- Modality
- GAS (Genetic analysis systems)
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of heliox in chronic obstructive pulmonary disease (COPD), sponsored by Air Liquide. Primary endpoint: Reduction of Non-Invasive Ventilation failure at 10 days. Started May 2010; status: terminated.
02
Drugs
heliox
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01155310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01155310.